The Effects of Super-Flux (High Performance) Dialyzer on Plasma Glycosylated Pro-B-Type Natriuretic Peptide (proBNP) and Glycosylated N-Terminal proBNP in End-Stage Renal Disease Patients on Dialysis
Background Plasma BNP levels are predictive of prognosis in hemodialysis patients. However, recent studies showed that the current BNP immunoassay cross-reacts with glycosylated proBNP, and the NT-proBNP assay underestimates glycosylated NT-proBNP. In addition, the recently developed high performance dialyzer removes medium-sized molecular solutes such as β2-microgloburin. We therefore investigated the effects of high performance dialysis on measured levels of glycosylated proBNP, glycosylated NT-proBNP and other BNP-related peptides in end-stage renal disease (ESRD) patients on hemodialysis. Method The relationships between clinical parameters and BNP-related molecule were also investigated. We used our newly developed immunoassay to measure plasma total BNP and proBNP in 105 normal subjects and 36 ESRD patients before and after hemodialysis. Plasma NT-proBNP was measured using Elecsys II after treatment with or without deglycosylating enzymes. We also measured plasma ANP and cGMP using radioimmunoassays. Results All the measured BNP-related peptides were significantly higher in ESRD patients than healthy subjects. Total BNP (？38.9%), proBNP (？29.7%), glycoNT-proBNP (？45.5%), nonglycoNT-proBNP (？53.4%), ANP (？50.4%) and cGMP (？72.1%) were all significantly reduced after hemodialysis, and the magnitude of the reduction appeared molecular weight- dependent. Both the proBNP/total BNP and glycoNT-proBNP/nonglycoNT-proBNP ratios were increased after hemodialysis. The former correlated positively with hemodialysis vintage and negatively with systolic blood pressure, while the latter correlated positively with parathyroid hormone levels. Conclusion These results suggest that hemodialysis using super-flux dialyzer removes BNP-related peptides in a nearly molecular weight-dependent manner. The ProBNP/total BNP and glycoNT-proBNP/nonglycoNT-proBNP ratios appear to be influenced by hemodialysis-related parameters in ESRD patients on hemodialysis.
References
[1]
Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, et al. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195–203. doi: 10.1161/01.cir.90.1.195
[2]
Nishikimi T, Kuwahara K, Nakao K (2011) Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 57: 131–140. doi: 10.1016/j.jjcc.2011.01.002
[3]
Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69: 318–328. doi: 10.1016/j.cardiores.2005.10.001
[4]
Weber M, Dill T, Deetjen A, Neumann T, Ekinci O, et al. (2006) Left ventricular adaptation after atrial septal defect closure assessed by increased concentrations of N-terminal pro-brain natriuretic peptide and cardiac magnetic resonance imaging in adult patients. Heart 92: 671–675. doi: 10.1136/hrt.2005.065607
[5]
Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, et al. (1996) Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28: 22–30. doi: 10.1161/01.hyp.28.1.22
[6]
Nishikimi T, Futoo Y, Tamano K, Takahashi M, Suzuki T, et al. (2001) Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 37: 1201–1208. doi: 10.1053/ajkd.2001.24523
[7]
Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50: 2357–2368. doi: 10.1016/j.jacc.2007.09.021
[8]
Nishikimi T, Minamino N, Ikeda M, Takeda Y, Tadokoro K, et al. (2010) Diversity of molecular forms of plasma brain natriuretic peptide in heart failure–different proBNP-108 to BNP-32 ratios in atrial and ventricular overload. Heart 96: 432–439. doi: 10.1136/hrt.2009.178392
[9]
Nishikimi T, Okamoto H, Nakamura M, Ogawa N, Horii K, et al. (2013) Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure. PLoS One 8: e53233. doi: 10.1371/journal.pone.0053233
[10]
Schellenberger U, O’Rear J, Guzzetta A, Jue RA, Protter AA, et al. (2006) The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 451: 160–166. doi: 10.1016/j.abb.2006.03.028
[11]
Liang F, O’Rear J, Schellenberger U, Tai L, Lasecki M, et al. (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49: 1071–1078. doi: 10.1016/j.jacc.2006.10.063
[12]
Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, et al. (2008) Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 54: 866–873. doi: 10.1373/clinchem.2007.100040
[13]
Jackson S (1985) Anatomy & Physiology for Nurses. Nurses’ Aids Series (9th ed.).
[14]
Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, et al. (2012) The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 98: 152–161. doi: 10.1136/heartjnl-2011-300102
[15]
Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, et al. (2008) Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 54: 619–621. doi: 10.1373/clinchem.2007.097998
[16]
Hammerer-Lercher A, Halfinger B, Sarg B, Mair J, Puschendorf B, et al. (2008) Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 54: 858–865. doi: 10.1373/clinchem.2007.090266
[17]
Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, et al. (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350: 1349–1353. doi: 10.1016/s0140-6736(97)06031-5
[18]
Davis M, Espiner E, Richards G, Billings J, Town I, et al. (1994) Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343: 440–444. doi: 10.1016/s0140-6736(94)92690-5
[19]
Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, et al. (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95: 948–954. doi: 10.1016/j.amjcard.2004.12.032
[20]
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161–167. doi: 10.1056/nejmoa020233
[21]
Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, et al. (1997) Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 47: 287–296. doi: 10.1046/j.1365-2265.1997.2361058.x
[22]
Jourdain P, Funck F, Bellorini M, Guillard N, Loiret J, et al. (2003) Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 5: 155–160. doi: 10.1016/s1388-9842(02)00247-7
[23]
Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, et al. (1996) Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28: 988–994. doi: 10.1161/01.hyp.28.6.988
[24]
Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, et al. (2004) Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43: 416–422. doi: 10.1016/j.jacc.2003.08.046
[25]
Niizuma S, Iwanaga Y, Yahata T, Tamaki Y, Goto Y, et al. (2009) Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. Clin Chem 55: 1347–1353. doi: 10.1373/clinchem.2008.121236
[26]
Wang AY, Lam CW, Yu CM, Wang M, Chan IH, et al. (2007) N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 18: 321–330. doi: 10.1681/asn.2005121299
[27]
Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, et al. (2001) Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59: 1559–1566. doi: 10.1046/j.1523-1755.2001.0590041559.x
[28]
Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, et al. (2007) N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 71: 548–554. doi: 10.1038/sj.ki.5002087
[29]
Satyan S, Light RP, Agarwal R (2007) Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 50: 1009–1019. doi: 10.1053/j.ajkd.2007.08.017
[30]
Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, et al. (2001) Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 76: 1111–1119. doi: 10.4065/76.11.1111
[31]
Niizuma S, Iwanaga Y, Yahata T, Goto Y, Kita T, et al. (2009) Plasma B-type natriuretic peptide levels reflect the presence and severity of stable coronary artery disease in chronic haemodialysis patients. Nephrol Dial Transplant 24: 597–603. doi: 10.1093/ndt/gfn491
[32]
Sivalingam M, Suresh M, Farrington K (2011) Comparison of B-type natriuretic peptide and NT proBNP as predictors of survival in patients on high-flux hemodialysis and hemodiafiltration. Hemodial Int 15: 359–365. doi: 10.1111/j.1542-4758.2011.00557.x
[33]
Schluter KD, Piper HM (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37: 34–41. doi: 10.1016/s0008-6363(97)00194-6
[34]
Sheen V, Bhalla V, Tulua-Tata A, Bhalla MA, Weiss D, et al.. (2007) The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 153: 244 e241–245.
